<DOC>
	<DOCNO>NCT00002172</DOCNO>
	<brief_summary>To provide product expanded access program HIV-infected patient CD4 count less 300 cells/ml .</brief_summary>
	<brief_title>An Expanded Access Open-Label , Compassionate Use Protocol Remune HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositivity . CD4 count &lt; 300 cells/ml . NOTE : If patient 's CD4 count 275 300 cells/ml , patient must either rescreen Study 806 wait 6 month enter expanded access program . Patient must fail intolerant comparable alternative market therapy must candidate therapy . Patient must meet inclusion criterion Remune trial . Patient must laboratory test within specify limit . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Clinically significant cardiac , hepatic , renal , gastrointestinal dysfunction . Current participation Remune study . Concurrent Medication : Excluded : Use immunemodulating drug . Induction therapy initiation new treatment regimen AIDSdefining condition . Patients follow prior condition exclude : Previous participation Remune study . Prior Medication : Excluded : Use immunemodulating drug within 3 month Day 1 visit . Induction therapy initiation new treatment regimen AIDSdefining condition within 30 day Day 1 visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1995</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Salk HIV Immunogen</keyword>
</DOC>